Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jan 25, 2025. (Total: 235671Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 10 (of 10 Records)

Query Trace: Thrombocytopenia and BID[original query]
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Cancer chemotherapy and pharmacology 2011 Jun 67 (6): 1323-31.
Hong Junshik, Han Sae-Won, Ham Hye Seon, Kim Tae-Yong, Choi In Sil, Kim Byung-Su, Oh Do-Youn, Im Seock-Ah, Kang Gyeong Hoon, Bang Yung-Jue, Kim Tae-Y
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91.
Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth
Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Clinical breast cancer 2017 9 18 (1): e135-e142.
Anampa Jesus, Chen Alice, Wright John, Patel Margi, Pellegrino Christine, Fehn Karen, Sparano Joseph A, Andreopoulou Ele
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Oncotarget 2017 Oct 8 (45): 79175-79187.
Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Cancer medicine 2018 May .
Werner Theresa L, Sachdev Jasgit, Swisher Elizabeth M, Gutierrez Martin, Kittaneh Muaiad, Stein Mark N, Xiong Hao, Dunbar Martin, Sullivan Danielle, Komarnitsky Philip, McKee Mark, Tan Antoinette
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
British journal of cancer 2018 12 120 (3): 286-293.
de Weger Vincent A, de Jonge Maja, Langenberg Marlies H G, Schellens Jan H M, Lolkema Martijn, Varga Andrea, Demers Brigitte, Thomas Koruth, Hsu Karl, Tuffal Gilles, Goodstal Samantha, Macé Sandrine, Deutsch Er
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Cancer chemotherapy and pharmacology 2019 Aug .
Nuthalapati Silpa, Stodtmann Sven, Shepherd Stacie Peacock, Ratajczak Christine K, Mensing Sven, Menon Rajeev, Xiong H
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Investigational new drugs 2019 10 38 (4): 1096-1107.
van der Noll Ruud, Jager Agnes, Ang Joo Ern, Marchetti Serena, Mergui-Roelvink Marja W J, de Bono Johann S, Lolkema Martijn P, de Jonge Maja J A, van der Biessen Diane A, Brunetto Andre T, Arkenau Hendrik-Tobias, Tchakov Ilian, Beijnen Jos H, De Grève Jacques, Schellens Jan H
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Cancer science 2021 1 112 (3): 1123-1131.
Munakata Wataru, Shirasugi Yukari, Tobinai Kensei, Onizuka Makoto, Makita Shinichi, Suzuki Rikio, Maruyama Dai, Kawai Hidetsugu, Izutsu Koji, Nakanishi Tadashi, Shiba Sari, Hojo Seichiro, Ando Kiyos
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
BMC cancer 2023 4 23 (1): 331.
Hu Xingsheng, Cui Xinge, Wang Ziping, Liu Yunpeng, Luo Ying, Zhong Wei, Zhao Hui, Yao Mengxing, Jiang Da, Wang Mingxia, Chen Minjiang, Zheng Xin, Ding Lieming, Wang Yang, Yuan Xiaobin, Wu Pengxiang, Hu Bei, Han Xiaohong, Shi Yuank
TOP